German Pharmacists Oppose Reclassifying Cannabis As A Narcotic Drug
German pharmacist Florian Sedlmeier and other members of Germany’s pharmacy industry are publicly pushing back on an effort by cannabis opponents in Germany to reclassify cannabis as a narcotic drug in the European nation. Cannabis was removed from Germany’s Narcotics List last year as part of the enactment of the CanG law.
“Pharmacist Florian Sedlmeier warns against reclassifying medicinal cannabis as a narcotic drug (BtM). Such a step would increase the bureaucratic burden and make it more difficult to provide patients with rapid care, ” stated the German Cannabis Business Association (BvCW) in its recent newsletter, citing an article from apotheke-adhoc. “He considers the concern expressed by SPD Health Minister Clemens Hoch that medicinal cannabis can be ordered too easily online to be understandable, but stresses that pharmacies carefully check prescriptions and licenses.”
“Reclassification as a narcotic would not curb the black market, but rather limit storage and the range of products available in pharmacies. Pharmacies are currently benefiting from the fact that medicinal cannabis no longer has to be stored in safes and can be prescribed more easily using e-prescriptions or model 16 forms. Instead of returning to the narcotic prescription requirement, Sedlmeier proposes stricter control of medical prescriptions, for example by requiring doctors to submit prescriptions and possible sanctions in the event of misuse.” BvCW also reported.
Germany implemented the first provisions of its new adult-use cannabis legalization law on April 1st, 2024, legalizing the personal cultivation, possession, and consumption of cannabis by adults. Another major component of the first provisions involved the previously referenced removal of cannabis from the nation’s Narcotics List.
According to a recent report by the Bloomwell Group, prescriptions for medical cannabis in Germany increased by roughly 1,000% between March 2024 and December 2024. The report also found that prices for medical cannabis products are decreasing in Europe’s largest medical cannabis market.
Another component of Germany’s new legalization model involves permitting cultivation associations. The application process for cultivation associations started on July 1st, 2024, and to date, 83 cultivation applications have been approved, with hundreds more working their way through the process.
Germany was already home to the largest legal medical cannabis industry in Europe before the enactment of adult-use legalization, and changes in medical cannabis policies and regulations in 2024 have resulted in a domestic medical cannabis boom, as demonstrated by the data in Bloomwell’s recent report.
Legal medical cannabis imports continue to rise in Germany as well. During the first three full months following Germany’s enactment of the CanG adult-use legalization law (Q3), legal medical cannabis imports increased by over 70% compared to the previous period.
Alex Rogers, founder and CEO of the International Cannabis Business Conference, recently visited Helios’ Munich pharmacy location to see their world-class operations firsthand, which can be viewed in the video embedded below. The video provides a great glimpse into Germany’s emerging legal medical cannabis industry: